SOPHiA DDM™ Community Pharmacogenomics Solution

Pharmacogenomics solution for NGS analysis that combines a capture enrichment kit with the analytical capabilities of the SOPHiA DDM™ platform. It is designed to evaluate and report genomic variants associated with pharmacogenomics in an accelerated manner.

Detailed description

Operating principle

The solution integrates a capture enrichment kit with the bioinformatics analysis of the SOPHiA DDM™ platform. The panel covers coding and some non-coding regions of 41 genes and 1 pseudogene associated with pharmacogenomics.

The probe design is highly optimized to ensure a high percentage of on-target reads and uniformity of coverage, even in GC-rich regions, including the first exon.

Pharmacogenomics solution

Clinical applications

Product intended for pharmacogenomic analysis using NGS, allowing the identification and characterization of genetic variants associated with drug response.

It facilitates the evaluation of relevant genomic information to support the interpretation of interindividual variability in pharmacological response, through the characterization of genes of pharmacogenomic interest and the determination of genotypes and star alleles.

Benefits

Integrated workflow, from target region enrichment to bioinformatics analysis. Simplifies the detection, annotation and evaluation of pharmacogenomic variants. Facilitates interpretation through specific filtering and annotation tools. Generates pharmacogenomics-specific results and output files, including genotypic information for the genes analyzed. Specialized analysis of complex genes such as CYP2D6. Reduces the time required for the analysis and interpretation of results. Secure and unlimited data storage. Access to the SOPHiA GENETICS community, promoting the exchange of knowledge about variants.

Intended audience/user

Intended for molecular genetics, pharmacogenomics and genomic diagnostics laboratories, as well as professionals specializing in the analysis and interpretation of genetic variants related to drug response.

Considerations
Required starting material: 50 ng of DNA Starting sample type: DNA extracted from peripheral blood

Key aspects

Integrated solution for capture enrichment and bioinformatics analysis for pharmacogenomics.
Coverage of 41 genes and 1 pseudogene of pharmacogenomic interest.
Detection of SNVs, indels, CNVs and star alleles.
Specialized module for CYP2D6, including analysis of CNVs, promoter regions/UTRs and determination of star alleles.
Specific annotation and filtering tools to streamline variant interpretation.
Generation of a pharmacogenomic report with the genotypic status of the genes included in the panel.
High analytical performance in terms of sensitivity, precision and specificity.
Secure data storage.
Integration with the SOPHiA GENETICS community to facilitate the exchange of knowledge about variants.

Presentation details

Product code: CS2532ILLRGLY10

Area:

Molecular Genetics, Pharmacogenomics, Targeted study of specific pathologies
Consult our experts

Google reCaptcha: Invalid site key.

Related products

SureSelect Cancer CGP Assay

Targeted-enrichment NGS pan-cancer panel for comprehensive genomic profiling (CGP) of solid tumours. Designed to detect somatic variants at DNA level (SNVs, indels, CNVs, translocations) and RNA level (gene fusions), as well as to assess complex immuno-oncology biomarkers such as tumour mutational burden (TMB), microsatellite instability (MSI) and homologous recombination deficiency (HRD). Detailed Description Operating principle…
Agilent
Next Generation Sequencing (NGS)

SeqOne HRD Solution con Agilent SureSelect CD HRR17 Panel

HRD analysis solution combining low-coverage whole-genome sequencing (shallow/low-pass WGS) and a targeted gene panel to detect genomic instability, BRCA1/2 alterations and other genes related to homologous recombination. It is designed for laboratories wishing to implement HRD testing in-house with an automated, efficient and clinically validated workflow. Detailed Description SeqOne’s HRD solution combines shallow WGS and…
Agilent
Next Generation Sequencing (NGS)

OncoSELECT®

Comprehensive targeted liquid biopsy assay designed to support decision-making in oncology through the analysis of 74 clinically relevant genes. The solution encompasses everything from library preparation reagents to bioinformatics analysis, clinical interpretation and the generation of detailed reports. 3.- Detailed Description Operating principle OncoSELECT® is an advanced liquid biopsy panel based on circulating cell-free DNA…
OncoDNA
Next Generation Sequencing (NGS)

Agilent SureSelect Human All Exon V8.

High-performance exome for the enrichment of human coding regions, with updated coverage of RefSeq, CCDS and GENCODE, including the TERT promoter and difficult-to-capture exons. 3.- Detailed Description Operating principle SureSelect Human All Exon V8 is based on NGS library preparation and capture enrichment of target regions of the human exome. The workflow is compatible with…
Agilent
Next Generation Sequencing (NGS)